Results 121 to 130 of about 231,717 (193)

Monitoring the Electrical Phenotype of Transthyretin Amyloid Cardiomyopathy in the Era of Disease-Modifying Therapy. [PDF]

Circ Rep
Yonezu K, Kondo H, Takahashi N.
europepmc   +1 more source

Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy.

JAMA Cardiol
Hauptmann L, Schwarting SK, Tomasoni D, Zanders L, Kronberger C, Koschatko S, Autherith M, Singer K, Jantsch C, Heitzinger G, Demirel C, Duca F, Kammerlander A, Bordignon L, Guidi Colombi G, Schwegel N, Serenelli M, Porcari A, Kieviet LC, Verheyen N, Oerlemans MIFJ, Papathanasiou M, Hengstenberg C, Sinagra G, Hausleiter J, Adamo M, Bartko PE, Nitsche C.   +27 more
europepmc   +1 more source

A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study. [PDF]

J Comp Eff Res
Debonnaire P, Zwetsloot PP, Pfister R, Llàcer P, Cipriani A, Milani P, Bonderman D, Ohlmeier C, Evers T, Wyss R, Patorno E, Doshi R, Beisel J, Coleman CI, Aguiar C, Ripoll-Vera T.   +15 more
europepmc   +1 more source

Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy. [PDF]

Cardiol Ther
Fumagalli C, Cappelli F, Maurer MS, Aus dem Siepen F, Dispenzieri A, Garcia-Pavia P, Hanna M, Carlsson M, Damy T.   +8 more
europepmc   +1 more source

Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States. [PDF]

J Am Heart Assoc
Alexander KM, Dasgupta NR, Mathisen J, Møller SG, Tvistholm A, Maurer MS.   +5 more
europepmc   +1 more source

Artificial Intelligence for the Diagnosis of Transthyretin Amyloid Cardiomyopathy: A Systematic Review of Machine Learning Application. [PDF]

Cardiol Res Pract
Jamileh E, Elmewafy AT, Qadeer MA, Zulfiqar Z, Kang K, Hosseini K, Antoun I.   +6 more
europepmc   +1 more source

From stabilization to silencing in transthyretin amyloid cardiomyopathy: why sequencing should be treat-to-trajectory, not 'one-and-done'. [PDF]

Eur Heart J Cardiovasc Pharmacother
Albulushi A, Al Rashdi T, Al-Farhan H.
europepmc   +1 more source

Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis. [PDF]

Cardiol Ther
Fontana M, Aimo A, Grogan M, Crespo-Leiro MG, Maurer MS, Siepen FAD, Hanna M, Delgado D, Carlsson M, Damy T, Davis MK.   +10 more
europepmc   +1 more source

p.(V142I)-Associated Variant Transthyretin Amyloid Cardiomyopathy Complicating Complex Congenital Heart Disease: A Lethal Combination. [PDF]

JACC Case Rep
Zathar Z, Choy CH, Al-Sakini N, Pinney J, Banerjee P, Adamson DL, Gillmore JD, Fontana M, Steeds RP, Moody WE.   +9 more
europepmc   +1 more source

Pathways for Patients with Transthyretin Amyloid Cardiomyopathy from a District General Hospital Perspective. [PDF]

J Cardiovasc Dev Dis
Kwok CS, Hamnett P, Palmer M, Chong D.
europepmc   +1 more source